Abicipar Pegol
- Generic Name
- Abicipar Pegol
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1327278-94-3
- Unique Ingredient Identifier
- M55Q728KNA
- Background
Abicipar Pegol has been used in trials studying the treatment of Macular Edema and Macular Degeneration.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Allergan
- Target Recruit Count
- 124
- Registration Number
- NCT03539549
- Locations
- 🇺🇸
Retina Consultants of Orange County, Fullerton, California, United States
🇺🇸N. California Retina Vitreous Associates Medical Group, INC., Mountain View, California, United States
🇺🇸Georgia Retina, P.C., Marietta, Georgia, United States
Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Allergan
- Target Recruit Count
- 11
- Registration Number
- NCT03335852
- Locations
- 🇯🇵
Takeuchi Eye Clinic, Taito-ku, Tokyo, Japan
🇯🇵Kimura Eye and Internal Medicine Hospital, Kure, Hiroshima, Japan
🇯🇵Musashi Dream Clinic, Tennouji-ku, Osaka, Japan
Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2018-02-08
- Lead Sponsor
- Allergan
- Target Recruit Count
- 30
- Registration Number
- NCT02859766
- Locations
- 🇺🇸
Atlantis Retina Institute (Atlantis Eyecare), Huntington Beach, California, United States
🇺🇸Retina Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Jacobs Retina Center, Shiley Eye Institute, UCSD, La Jolla, California, United States
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 949
- Registration Number
- NCT02462486
- Locations
- 🇺🇸
Paducah Retinal Center, Paducah, Kentucky, United States
🇺🇸Maculacare - New York, New York, New York, United States
🇺🇸Retina Vitreous Surgeons of Central NY, PC, Syracuse, New York, United States
A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Allergan
- Target Recruit Count
- 939
- Registration Number
- NCT02462928
- Locations
- 🇨🇱
Instituto Oftalmologica Profesor Arentsen, Santiago, Región Metropolitana, Chile
🇵🇭Asian Eye Institute, Makati City, Metro Manila, Philippines
🇵🇭St. Luke's Medical Center, Quezon City, Metro Manila, Philippines
A Study of Abicipar Pegol in Patients With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 151
- Registration Number
- NCT02186119
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Allergan
- Target Recruit Count
- 25
- Registration Number
- NCT02181504
- Locations
- 🇯🇵
Nihon University Hospital, Chiyoda-ku,Tokyo, Japan
🇯🇵1 Fukushima Medical University, Fukushima-shi, Japan
🇯🇵Kyushu University Hospital, Kita-ku, Fukuoka-shi Fukuoka, Japan
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 25
- Registration Number
- NCT02181517
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.